ERBB2 and gastric cancer: However, later studies demonstrated that gastric cancer cells that exhibit dramatic reductions in the expression of various tyrosine kinase receptors (TKRs), including HER2/ERBB2, are resistant to TKR inhibitors but sensitive to mubritinib.